North America Continuous Glucose Monitoring Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

North America Continuous Glucose Monitoring Market Trends and Insights

Rising Prevalence Of Diabetes & Earlier Diagnosis

Diabetes prevalence reached 38.4 million in the United States in 2024, 3.7 million in Canada in 2025, and 12.4 million in Mexico in 2025. Screening guidelines now recommend testing all adults aged 35+ and overweight adults with a risk factor, expanding the addressable base by roughly 15 million individuals^{[1]Centers for Disease Control and Prevention, “National Diabetes Statistics Report,” CDC, cdc.gov}. Newly diagnosed adults receive CGM within 90 days because randomized evidence shows a 0.9% additional A1c reduction versus finger-stick monitoring. Commercial insurers mirrored the science by adding first-line CGM coverage for non-insulin users in 2025^{[2]American Diabetes Association, “Standards of Care in Diabetes—2025,” Diabetes Care, diabetes.org}. The result is a durable, long-tail driver across the North American continuous glucose monitoring market.

Rapid Uptake of Remote Monitoring & Telehealth Integration

CPT codes 99453, 99454, and 99457 reimburse remote physiologic data review, creating a recurring USD 64 monthly revenue stream per CGM patient. The Veterans Health Administration cut in-person endocrinology visits 38% after systemwide CGM-telehealth rollout in 2025 while sustaining glycemic outcomes. Kaiser Permanente’s virtual clinic documented a 1.2% mean A1c drop among 4,800 enrollees by pairing CGM with asynchronous coaching. FDA guidance clarified that cloud-connected CGM platforms qualify for RPM billing, ending payer ambiguity ^{[3]U.S. Food and Drug Administration, “Real-Time Continuous Glucose Monitoring Systems Guidance,” fda.gov}. These forces intertwine reimbursement and telehealth growth, lifting the North American continuous glucose monitoring market.

Sensor Miniaturization & Accuracy Breakthroughs

Abbott’s FreeStyle Libre 3 shrank sensor volume 70% and achieved 7.9% MARD. Dexcom’s G7 cut warm-up to 30 minutes and landed at 8.2% MARD. Senseonics’ Eversense 365 delivers 365-day wear and removes adhesive dermatitis risk for the estimated 10% of users with skin reactions. FDA draft guidance suggests CGM with <10% MARD may support insulin dosing without confirmatory finger sticks, unlocking an 8.4 million-strong type 1 population. Accuracy gains, therefore, amplify both clinical utility and payer acceptance. 

Integration With Automated Insulin Delivery Systems

Tandem’s Control-IQ held a significant U.S. automated-delivery share in 2025, operating exclusively on Dexcom CGM inputs. Insulet shipped 1.2 million Omnipod 5 pods in 2024, a 68% increase driven by Dexcom sensor pairing. Beta Bionics’ iLet bionic pancreas, approved May 2024, doses insulin using only patient weight plus CGM data. ADA 2025 guidelines recommend automated delivery for all type 1 patients who can safely use the technology. Medicare now requires ≥80% CGM usage to qualify for pump reimbursement, effectively hard-linking sensor adoption to insulin-pump funding. 

High Device & Consumable Costs to Payers & Patients

A 10-day sensor wholesales for USD 75-95, producing yearly consumable costs up to USD 3,467 before insurance. Medicare Part B’s 20% coinsurance still leaves users with USD 547-693 out-of-pocket annually. Medicaid coverage is fragmentary: 38 states reimburse CGM for type 1, only 22 for non-insulin type 2, excluding 14 million beneficiaries. Mexico’s social-security formulary omits CGM entirely, forcing retail prices equal to 12-16% of the monthly minimum wage, restricting adoption to affluent urban consumers. Elevated cost, therefore, moderates penetration and dampens the North America continuous glucose monitoring market CAGR.

GLP-1 Weight-Loss Drugs Reducing Testing Frequency

Ozempic and Mounjaro posted combined U.S. sales of USD 14.3 billion in 2024, reducing A1c 1.5-2.0 percentage points and flattening glucose excursions. A Lancet study showed CGM time-in-use dropping from 85% to 62% six months post-GLP-1 initiation. Cigna now limits CGM coverage to patients with A1c > 8% or documented hypoglycemia, excluding 40% of GLP-1 users who achieve A1c < 7%. This pharmacologic substitution tempers addressable demand in the non-insulin type 2 cohort.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Component: Sensors Dominate on Accuracy and Longevity Gains

Sensors accounted for 68.9% of the North America continuous glucose monitoring market share in 2025 and are projected to expand at a 16.87% CAGR through 2031. Their integration of Bluetooth Low Energy allows disposable form factors to communicate directly with smartphones, removing transmitters and trimming bill-of-material cost by 22%. Wearable sensors represent 92% of revenue; implantables grow faster at 21.3% by alleviating dermatitis complaints. Transmitters and receivers decline as stand-alone categories but persist among pediatric and senior users who lack smartphones.

Continued miniaturization underpins the competitive edge: Abbott’s 5-mm Libre 3 disk and Dexcom’s sleeker G7 both meet ISO 15197:2013 accuracy thresholds, positioning sensors as the hardware linchpin of the North America continuous glucose monitoring market size for the foreseeable future. FDA interoperability rules will further commoditize transmitters, concentrating value creation in sensor chemistry, wear duration, and algorithmic signal processing.

By Demography: Pediatric Segment Surges on Label Expansions

Adults generated 71.2% of 2025 revenue, but the pediatric group will grow at 18.92% CAGR after regulatory age floors fell to 2 years. The International Society for Pediatric and Adolescent Diabetes finds that CGM reduces hypoglycemia risk by 72% versus finger-stick monitoring. Ontario’s Assistive Devices Program funds 80% of the device cost for children, expanding access to 12,000 users. U.S. school-access legislation now allows students to view live glucose on smartwatches, normalizing classroom use. Meanwhile, adult adoption accelerates in the 35 million-strong non-insulin type 2 segment now served by over-the-counter Stelo and Libre 3. The demographic mix will therefore rebalance the North America continuous glucose monitoring market size toward younger cohorts without sacrificing adult revenue. 

By End User: Home Care Leads on Telehealth and Reimbursement Tailwinds

Home settings captured 85.4% revenue in 2025 and will sustain a 17.87% CAGR thanks to RPM billing codes and direct-to-consumer shipment. Veterans Health Administration data show 38% fewer in-person visits after CGM-telehealth deployment. Private insurers erased prior authorization for millions of non-insulin users, further entrenching home distribution. Hospitals remain a niche, bound by infection-control protocols that prefer arterial lines for inpatients, while specialty centers focus on intensive education.

Remote data review is proving cost-effective; hence, health-system stakeholders increasingly steer patients toward at-home initiation, reinforcing the home-care dominance of the North America continuous glucose monitoring market share through 2031. 

Geography Analysis

The United States accounted for 88.5% of 2025 revenue, energized by Medicare’s national coverage determination and over-the-counter clearances that enable pharmacy and e-commerce distribution. Removal of prescription requirements is forecast to add 4.2 million first-time users by 2027. However, surging GLP-1 uptake has already reduced CGM use frequency by 27% among type 2 cohorts, tempering upside.

Canada will post the fastest national growth at 16.43% CAGR through 2031 as Ontario, Quebec, and British Columbia eliminate prior-authorization and extend coverage to insulin-using adults. Health Canada approvals of Dexcom G7 and Libre 3 bring technology parity with the United States.

Mexico represents roughly 3% of regional value because social-security formularies exclude CGM and retail sensors cost MXN 1,500-2,000 (USD 88-117) each, 12-16% of the minimum wage. Private insurance penetration below 8% confines adoption to affluent urban consumers despite the nation’s 12.4 million-person diabetes burden.

Regulatory Landscape

In the United States, continuous glucose monitoring (CGM) systems are regulated by the U.S. Food and Drug Administration (FDA) largely through Class II pathways for integrated CGM (iCGM), reflecting their role in insulin dosing and automated insulin delivery (AID) interoperability. In May 2026, the FDA published final guidance on submitting CGM data in clinical trials, tightening expectations for standardized CGM datasets in marketing submissions and emphasizing the role of software, connectivity, and data integrity as CGM expands into remote monitoring workflows.

In Canada, Health Canada regulates CGM under the Medical Devices Regulations (SOR/98-282), where systems with meaningful risk from erroneous readings are commonly treated as Class III devices requiring a Medical Device Licence Application. Cross-border regulatory alignment is supported by reliance on consensus standards and the International Medical Device Regulators Forum (IMDRF) Table of Contents format, which manufacturers use to structure technical documentation while addressing quality management, risk management, and software life-cycle controls needed for cloud-connected CGM platforms.

Market Opportunities and Future Outlook

Over-the-counter (OTC) expansion and earlier-age access open additional whitespace beyond intensive insulin users, particularly for adults and pediatrics managed outside specialty endocrinology. In June 2026, the FDA cleared Dexcom's Stelo for children aged 2 to 18 who do not use insulin, extending OTC-style access into pediatric use cases that are already benefiting from label expansions and school-based acceptance of live glucose viewing. This widens the channel mix toward pharmacy and direct-to-consumer models and supports use cases connected to employer-sponsored wellness programs and clinician remote physiologic monitoring workflows supported by CPT codes.

Supply resilience and domestic scale-up are also becoming an opportunity track, with manufacturers allocating capital to North American production footprints for next-generation systems. Roche announced a USD 550 million investment (May 2025) to expand its Indianapolis diagnostics manufacturing hub through 2030 and designated the site for Accu-Chek Smartguide CGM production, while Dexcom disclosed over USD 500 million of investment in San Diego during 2025 to support capacity expansion and R&D for future platforms. Alongside product evolution toward longer wear (for example, 15-day systems cleared in 2026) and implantable options that address adhesive-related dermatitis, these investments point to active commercialization efforts that vendors can leverage for broader payer coverage and new patient segments across the region.